Literature DB >> 9815247

Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis.

N P Juffermans1, A Verbon, S J van Deventer, W A Buurman, H van Deutekom, P Speelman, T van der Poll.   

Abstract

Lipopolysaccharide (LPS) is the principal stimulator of host defense against gram-negative bacteria. LPS-binding protein (LBP), bactericidal/permeability-increasing protein (BPI), and soluble CD14 (sCD14) bind LPS and regulate its toxicity. Lipoarabinomannan, a cell wall component of Mycobacterium tuberculosis, resembles LPS with respect to induction of inflammatory responses through recognition by LBP and sCD14. LBP, BPI, and sCD14 were measured in serum of 124 patients with tuberculosis in various stages of disease, in persons who had been in close contact with patients with contagious pulmonary tuberculosis, and in healthy controls. Levels of these LPS toxicity-regulating proteins were elevated in patients with active tuberculosis compared with those in contacts and controls and declined during treatment. The levels of LBP and sCD14 were higher in patients with fever and anorexia. LPS-regulating proteins may play a role in host defense during tuberculosis, presumably through interaction with lipoarabinomannan.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815247     DOI: 10.1086/314492

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  Serological markers of disease activity in tuberculosis and HIV infection.

Authors:  A Marchant
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14.

Authors:  J Karhukorpi; Y Yan; S Niemela; J Valtonen; P Koistinen; T Joensuu; P Saikku; R Karttunen
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

3.  Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment.

Authors:  S D Lawn; M O Labeta; M Arias; J W Acheampong; G E Griffin
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 4.  Innate immunity to Mycobacterium tuberculosis.

Authors:  Reinout van Crevel; Tom H M Ottenhoff; Jos W M van der Meer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

5.  Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects.

Authors:  Zahra Toossi; Nicholas T Funderburg; Sohani Sirdeshmuk; Christopher C Whalen; Maria W Nanteza; Denise F Johnson; Harriet Mayanja-Kizza; Christina S Hirsch
Journal:  J Infect Dis       Date:  2013-03-11       Impact factor: 5.226

6.  Recombinant soluble CD14 reduces severity of intramammary infection by Escherichia coli.

Authors:  Jai-Wei Lee; Max J Paape; Theodore H Elsasser; Xin Zhao
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

7.  CD14 contributes to pulmonary inflammation and mortality during murine tuberculosis.

Authors:  Catharina W Wieland; Gerritje J W van der Windt; W Joost Wiersinga; Sandrine Florquin; Tom van der Poll
Journal:  Immunology       Date:  2008-04-03       Impact factor: 7.397

8.  Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis.

Authors:  Masako Mizusawa; Mizuoho Kawamura; Mikio Takamori; Tetsuya Kashiyama; Akira Fujita; Motoki Usuzawa; Hiroki Saitoh; Yugo Ashino; Ikuya Yano; Toshio Hattori
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

9.  CD14 -159 C>T gene polymorphism with increased risk of tuberculosis: evidence from a meta-analysis.

Authors:  M Y Areeshi; Raju K Mandal; Aditya K Panda; Shekhar C Bisht; Shafiul Haque
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

10.  Soluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responses.

Authors:  Siri L Feruglio; Marius Trøseid; Jan Kristian Damås; Dag Kvale; Anne Ma Dyrhol-Riise
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.